Nerviano Medical Sciences

The largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.
Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Tiziana Life Sciences licenses milciclib from Nerviano Medical Sciences London, 20 January 2015 – Tiziana Life Sciences plc (“Tiziana”, “the Company”, AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, is pleased to announce that it has exclusively licensed milciclib from Nerviano Medical Sciences Group (“Nerviano”), an Italian company dedicated to the discovery and development of... Read more
Series of B-Raf inhibitors discovered by Nerviano Medical Sciences published on ChemMedChem Nerviano, Italy, December 11, 2014. Nerviano Medical Sciences researchers report the identification and optimization of one B-RAF inhibitor belonging to the chemical class of diarylthiazoles on the journal ChemMedChem (“Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect”.... Read more
Cellectis e Accelera siglano un accordo per il completamento degli studi preclinici di UCART19 di Cellectis, una nuova e promettente terapia per per leucemie e linfomi Milano (Italia) e Parigi (Francia), 9 giugno 2014 – Cellectis (Alternext: ALCLS), società leader nel campo delle terapie cellulari basate su linfociti T allogenici ingegnerizzati con recettori chimerici antigene-specifici (CAR), e Accelera, società del Gruppo Nerviano Medical Sciences che svolge servizi di Ricerca a contratto (CRO) e che collabora con aziende farmaceutiche e biotecnologiche a... Read more
Il Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica di Nerviano, ambasciatore della ricerca italiana sul cancro al Quirinale al cospetto del Presidente della Repubblica in occasione della Giornata Nazionale della Ricerca sul Cancro Milano, 6 novembre 2014 – È toccato al Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica del Centro Ricerche di Nerviano (MI) e Direttore dell'Istituto di Genetica presso il Comprehensive Cancer Center dell’Ohio State University, il prestigioso ruolo di ambasciatore della ricerca italiana in ambito oncologico nel mondo al cospetto del Presidente della Repubblica Giorgio... Read more
Nerviano Medical Sciences discloses novel molecules suitable for the generation of antibody drug conjugates at the World ADC, San Diego (USA) 2014 Nerviano, November 6, 2014 - Nerviano Medical Sciences disclosed data on novel molecules suitable for the generation of antibody drug conjugates at the meeting World ADC San Diego (USA), 26-29 October 2014. Antibody drug conjugates (ADCs) represent a valuable approach to cancer therapy whereby antibodies are combined with potent cytotoxic compounds for selective tumor cell delivery and... Read more

Nerviano Medical Sciences

Nerviano Medical SciencesWe fight cancer. Our mission is to identify innovative agents for clinical development in areas of unmet

Read more...

Accelera

AcceleraAccelera is committed to predicting and managing potential toxic, pharmacokinetic

Read more...

CLIOSS

Nerviano Medical SciencesCLIOSS operates as your partner in the clinical development and life-cycle management

Read more...

NerPharMa

NerpharmaNerPharMa is a leading player in high-containment contract

Read more...